IQVIA Holdings Inc. $IQV Holdings Cut by MetLife Investment Management LLC

Key Points

• MetLife Investment Management LLC reduced its stake in IQVIA Holdings Inc. by 4.5% during the first quarter, now holding 44,569 shares valued at approximately $7.86 million.
• In contrast, Jump Financial LLC significantly increased its stake in IQVIA by 717.6%, owning 59,200 shares worth around $10.44 million after purchasing 51,959 additional shares.
• IQVIA reported earnings of $2.81 per share, exceeding analysts' expectations, with revenue of $4.02 billion for the quarter, which was a 5.3% increase year-over-year.

MetLife Investment Management LLC cut its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,569 shares of the medical research company's stock after selling 2,101 shares during the quarter. MetLife Investment Management LLC's holdings in IQVIA were worth $7,858,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Jump Financial LLC grew its position in shares of IQVIA by 717.6% during the 1st quarter. Jump Financial LLC now owns 59,200 shares of the medical research company's stock worth $10,437,000 after buying an additional 51,959 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of IQVIA by 11.7% in the first quarter. Smartleaf Asset Management LLC now owns 957 shares of the medical research company's stock valued at $170,000 after purchasing an additional 100 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in IQVIA by 42.9% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 217,716 shares of the medical research company's stock worth $38,383,000 after buying an additional 65,332 shares in the last quarter. AlphaQuest LLC lifted its holdings in shares of IQVIA by 101.8% in the first quarter. AlphaQuest LLC now owns 13,349 shares of the medical research company's stock worth $2,353,000 after acquiring an additional 6,735 shares during the last quarter. Finally, Norinchukin Bank The raised its holdings in IQVIA by 13.8% in the 1st quarter. Norinchukin Bank The now owns 9,385 shares of the medical research company's stock valued at $1,655,000 after buying an additional 1,137 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Trading Up 0.6%

NYSE:IQV opened at $188.82 on Thursday. The stock has a 50-day simple moving average of $175.64 and a 200-day simple moving average of $168.11. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $32.10 billion, a P/E ratio of 27.33, a P/E/G ratio of 2.06 and a beta of 1.30. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Cowen reiterated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Robert W. Baird raised their price target on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Mizuho upped their price objective on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $228.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.